117 related articles for article (PubMed ID: 19570464)
1. [Isolation, identification and clinical significance of ascites-derived exosomes from patients with ovarian epithelial cancer].
Peng P; You Y; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):268-72. PubMed ID: 19570464
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
3. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma].
Wu M; Shen K; Lang JH; Huang RL; Huang HF; Pan LY
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1406-9. PubMed ID: 16029654
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
7. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
[TBL] [Abstract][Full Text] [Related]
8. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.
Keller S; König AK; Marmé F; Runz S; Wolterink S; Koensgen D; Mustea A; Sehouli J; Altevogt P
Cancer Lett; 2009 Jun; 278(1):73-81. PubMed ID: 19188015
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
11. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
12. Induction of a tumour-specific CTL response by exosomes isolated from heat-treated malignant ascites of gastric cancer patients.
Zhong H; Yang Y; Ma S; Xiu F; Cai Z; Zhao H; Du L
Int J Hyperthermia; 2011; 27(6):604-11. PubMed ID: 21846196
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
15. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
18. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
19. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.
Runz S; Keller S; Rupp C; Stoeck A; Issa Y; Koensgen D; Mustea A; Sehouli J; Kristiansen G; Altevogt P
Gynecol Oncol; 2007 Dec; 107(3):563-71. PubMed ID: 17900673
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]